Company Overview and News
The greenback has been steady this year with about 4.4% gains and got a solid impetus for an extended rally from central bank meets this week. In fact, possibilities of four rate hikes in the United States this year, an uptick in GDP growth guidance by the Fed and the release of solid retail sales data for May led the king currency to log the best week since 2016.
SPG.PRJ USDU SPG IWM EUM
The U.S. small-cap space has exhibited an impressive rally this year with the Russell 2000, posting its 18th record close for the year on Jun 6. Small-cap fund iShares Russell 2000 ETF (IWM - Free Report) is up 5.2% in the past one month and 17.9% in the last one year. So far this year, IWM has advanced 7.9% while the S&P 500 is up 2.8% (as of Jun 7, 2018).
HSC UNP TRI IWM
For the seventh week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs) in general, adding a little more than $29.6 billion for Thomson Reuters Lipper's fund flows week ended June 6, 2018. However, the headline number was misleading. Despite upbeat economic reports and a market rally during the flows week, fund investors were net redeemers of equity funds (-$4.
IJR IJR IWM SCHP SHY SCHR
A host of Trump’s anti-trade policies has been playing foul in the stock market, leading to increased market uncertainty and trade tensions between the United States and countries around the world. This is especially true given that Trump’s tariffs have sparked concerns related to global trade, economic growth and political stability (read: Trump, Tariff & Geopolitics Lead May: 10 Top ETF Stories).
VIG DB FXY IWM
The markets were mostly positive in May. The month of May was positive for my retirement account but not positive for all of the ETFs that I follow as will be shown below. The market, as measured by the S&P 500 index, closed 2.16% higher in May. As for my pension plan assets, I had a positive return in May. My first investment objective, preservation of capital, was achieved with my positive return of 2.
AGG EFA IWM
Geopolitical tensions, oil price movement and President Trump’s announcements hit the headlines in the month of May. Donald Trump made impactful announcements pertaining to deregulations, trade relations with other countries and sanctions against countries like Iran and Venezuela. Overall, markets remained upbeat barring some occasional dips.
AGG IVV ELY QQQ IEF VOO SPY EZU IVV IWM EEM
Small caps have outperformed large caps YTD, with the iShares Russell 2000 ETF (IWM) up nearly 7% compared to less than 3% for the SPY. Most of the outperformance has come in recent weeks and can be attributed in part to the trade war rhetoric. While the current status of the trade war is 'on hold', there's plenty of reasons to believe we are still in the early innings of trade negotiations. Investing in some small cap companies that are less exposed to foreign tariffs could be a winning strategy for the foreseeable future.
ESXB EVH CARO CHGG IWM
Eighteen months ago, small caps also looked poised to outperform but disappointed, I'll tell you why.
Small-cap stocks have been painting the town red this year, outshining large-caps, as is evident from the 5% year-to-date gains from iShares Russell 2000 ETF (IWM - Free Report) versus a 1.2% rise in the large-cap fund SPDR S&P 500 ETF (SPY - Free Report) . The ascent is more prominent this month as the Russell 2000 touched an all-time high.
URTY TRI IWM
Wall Street has been on a roller-coaster ride this year. Yet, the small-cap segment of the broader market has been outperforming, defying extremely volatility. This is especially true as the Russell 2000 is nearing its record levels with just less than 1% away from its peak (read: What Makes Small-Cap ETFs Winners This Year). Why Small Caps? Global sentiments have been deteriorating due to lack of progress in U.
FYC GD VTWO CSX IWM VBK
For the third week in a row, investors were net purchasers of fund assets (including those of conventional funds and ETFs), taking in a little more than $8.2 billion. Despite market gains during the week, fund investors were net redeemers of equity funds (-$231 million) while being net purchasers of money market funds (+$8.2 billion), municipal bond funds (+$167 million), and taxable bond funds (+$86 million) for the fund-flows week ended May 9, 2018.
BRK.A IVV QQQ AAPL IVV SCHO IWM SHY EEM
Small-cap stocks have been overriding large caps this year as evident from 2.6% year-to-date gains from iShares Russell 2000 ETF (IWM - Free Report) versus a 0.7% decline in the large-cap fund SPDR S&P 500 ETF (SPY - Free Report) . The upper hand is more pronounced in the last one-month frame as IWM was up 4.8% against 2.3% advancement in SPY.
FYC TNA VTWO UWM TRI JKK IWN IWM SMLL
Looking for broad exposure to the Small Cap Blend segment of the US equity market? You should consider the iShares Morningstar Small-Cap ETF (JKJ - Free Report) , a passively managed exchange traded fund launched on 06/28/2004.
LPLA IJR AVXS FHN IJR JKJ IWM FHN.PRA
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...
Silicon Investor Message Boards
This table lists all message boards related to IWM / iShares Russell 2000 ETF on message board site Silicon Investor.
|January Effect 2011||January Effect 2012|
|January Effect 2007||January Effect 2006|
|January Effect 2005|
as of ET